Renal Denervation in a Hypertensive Patient With End-Stage Renal Disease and Small Arteries: A Direction for Future Research
Article first published online: 3 OCT 2012
© 2012 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 14, Issue 11, pages 799–801, November 2012
How to Cite
Ott, C., Schmid, A., Ditting, T., Sobotka, P. A., Veelken, R., Uder, M. and Schmieder, R. E. (2012), Renal Denervation in a Hypertensive Patient With End-Stage Renal Disease and Small Arteries: A Direction for Future Research. The Journal of Clinical Hypertension, 14: 799–801. doi: 10.1111/jch.12017
- Issue published online: 5 NOV 2012
- Article first published online: 3 OCT 2012
- Manuscript received: June 15, 2012; revised: August 9, 2012; accepted: August 15, 2012
J Clin Hypertens (Greenwich). 2012;14:799–801. ©2012 Wiley Periodicals, Inc.
Sympathetic overactivity plays a crucial pathogenetic role in the maintenance and aggravation of arterial hypertension in patients with end-stage renal disease (ESRD). Renal denervation has been shown to be effective and safe in reducing blood pressure (BP) in patients with treatment-resistant hypertension; however, there are only case reports in hypertensive patients with ESRD and data are lacking about possibility of renal denervation in small renal arteries. A woman with uncontrolled treatment-resistant hypertension on chronic hemodialysis underwent bilateral native kidney, catheter-based renal denervation. Both native renal arteries were <4 mm. After 6 months without any change of antihypertensive medication or hemodialysis parameters, the authors observed a remarkable BP reduction of 38/30 mm Hg (from baseline 172/100 mm Hg to 134/70 mm Hg) as evaluated by 24-hour ambulatory BP monitoring. The authors report that renal denervation seems to be effective in controlling hypertension in patients with ESRD, even in cases of small renal arteries.